NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series
I'm PortAI, I can summarize articles.
NLS Pharmaceutics (NLSP) announced the expansion of its DOXA platform with the AEX-6xx series, developed with Aexon Labs, targeting arousal stability, cognition, and neuroprotection for conditions like Parkinson’s disease. This expansion aligns with its merger with Kadimastem to form NewCelX. The company secured $25 million in funding for future clinical programs. NLS Pharmaceutics focuses on therapies for CNS and neurodegenerative disorders and will be listed on Nasdaq as NewCelX Ltd. with a market cap of $3.15M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments